New immunosuppresor strategies in the treatment of murine lupus nephritis

Abstract

Renal involvement in systemic lupus erythematosus is a common complication that significantly worsens morbidity and mortality. Although treatment with corticosteroids and cytotoxic drugs may be useful in many cases, morbidity associated with these drugs and the relapsing nature of the disease make it necessary to develop new treatment strategies. Five-month old female NZB/W F1 mice were divided into the following groups: CYP group (n = 10), cyclophosphamide (CYP) 50 mg/kg intraperitoneally every 10 days; RAPA 1 group (n = 10) oral daily sirolimus (SRL), 1 mg/kg; RAPA 12 group (n = 13), oral daily SRL, 12 mg/kg; FTY group (n = 10), oral fingolimod (FTY720), 2 mg/kg three times per week. An additional group of 13 non-treated mice were used as a control (control group). Follow-up was performed over four months. Animal survival, body weight, anti-DNA antibodies and proteinuria were determined. Kidneys were processed for conventional histology and immunofluorescence for IgG and complement. Total histological score (HS) was the sum of mesangial expansion, endocapillary proliferation glomerular deposits, extracapillary proliferation, interstitial infiltrates, tubular atrophy and interstitial fibrosis. All treated groups had lower proteinuria at the end of the follow-up with respect to the control group (P < 0.0001). Serum anti-DNA antibodies were appropriately controlled in RAPA 1 and CYP groups, but not in FTY or RAPA 12 groups. SRL and CYP arrested, and perhaps reversed almost all histological lesions. FTY720 ameliorated histological lesions but did not control mesangial expansion or interstitial infiltrates. SRL produces great improvement in murine lupus nephritis, while FTY720 seems a promising alternative if used in appropriate doses.

Keywords

FTY720 immunosuppression lupus nephritis lupus therapy lupus treatment murine lupus sirolimus

Get full access to this article

View all access options for this article.

References

Donadio JV Jr , Hart GM , Bergstralh EJ , Holley KE . Prognostic determinants in lupus nephritis: a long-term clinicopathologic study . Lupus 1995; 4: 109–115 .

Russell PJ , Hicks JD , Burnet FM . Cyclophosphamide treatment of kidney disease in (NZB x NZW) F1 mice . Lancet 1966; 1: 1280–1284 .

Austin HA 3rd , Klippel JH , Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs . N Engl J Med 1986; 314: 614–619 .

Korbet SM , Lewis EJ , Schwartz MM , Reichlin M , Evans J , Rohde RD . Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group . Am J Kidney Dis 2000; 35: 904–914 .

Gourley MF , Austin HA 3rd , Scott D et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial . Ann Intern Med 1996; 125: 549–557 .

Ioannidis JP , Boki KA , Katsorida ME et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide . Kidney Int 2000; 57: 258–264 .

Mok CC , Ying KY , Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis . Arthritis Rheum 2004; 50: 2559–2568 .

Boumpas DT , Austin HA 3rd , Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis . Lancet 1992; 340: 741–745 .

Valeri A , Radhakrishnan J , Estes D et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study . Clin Nephrol 1994; 42: 71–78 .

10.

Corna D , Morigi M , Facchinetti D , Bertani T , Zoja C , Remuzzi G . Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease . Kidney Int 1997; 51: 1583–1589 .

11.

Chan TM , Li FK , Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group . N Engl J Med 2000; 343: 1156–1162 .

12.

Flanc RS , Roberts MA , Strippoli GF , Chadban SJ , Kerr PG , Atkins RC . Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials . Am J Kidney Dis 2004; 43: 197–208 .

13.

Foster MH. Relevance of systemic lupus erythematosus nephritis animal models to human disease . Semin Nephrol 1999; 19: 12–24 .

14.

Lefkowith JB , Gilkeson GS . Nephritogenic autoantibodies in lupus: current concepts and continuing controversies . Arthritis Rheum 1996; 39: 894–903 .

15.

Berden JH , Licht R , van Bruggen MC , Tax WJ . Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis . Curr Opin Nephrol Hypertens 1999; 8: 299–306 .

16.

Schmelzle T , Hall MN . TOR, a central controller of cell growth . Cell 2000; 103: 253–262 .

17.

Warner LM , Adams LM , Sehgal SN . Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus . Arthritis Rheum 1994; 37: 289–297 .

18.

Graler MH , Goetzl EJ . The immunosuppressant FTY720 downregulates sphingosine 1-phosphate G-protein-coupled receptors . Faseb J 2004; 18: 551–553 .

19.

Brinkmann V , Davis MD , Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors . J Biol Chem 2002; 277: 21453–21457 .

20.

Kovarik JM , Schmouder RL , Slade AJ . Overview of FTY720 clinical pharmacokinetics and pharmacology . Ther Drug Monit 2004; 26: 585–587 .

21.

Okazaki H , Hirata D , Kamimura T , Sato H , Iwamoto M , Yoshio T . Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus . J Rheumatol 2002; 29: 707–716 .

22.

Quigg RJ , Lim A , Haas M , Alexander JJ , He C , Carroll MC . Immune complex glomerulonephritis in C4-and C3-deficient mice . Kidney Int 1998; 53: 320–330 .

23.

Dumont FJ , Staruch MJ , Koprak SL , Melino MR , Sigal NH . Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin . J Immunol 1990; 144: 251–258 .

24.

Kay JE , Kromwel L , Doe SE , Denyer M : Inhibition of T and B lymphocyte proliferation by rapamycin . Immunology 1991; 72: 544–549 .

25.

DiJoseph JF , Sharma RN , Chang JY . The effect of rapamycin on kidney function in the Sprague-Dawley rat . Transplantation 1992; 53: 507–513 .

26.

Kahan BD , Podbielski J , Napoli KL , Katz SM , Meier-Kriesche HU , Van Buren CT . Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation . Transplantation 1998; 66: 1040–1046 .

27.

Mathis AS , Dave N , Knipp GT , Friedman GS . Drug-related dyslipidemia after renal transplantation . Am J Health Syst Pharm 2004; 61: 565–585; quiz 586–587 .

28.

Kahan BD. Sirolimus-based immunosuppression: present state of the art . J Nephrol 2004; 17 (Suppl 8): 32–39 .

29.

Pham PT , Pham PC , Danovitch GM et al. Sirolimus-associated pulmonary toxicity . Transplantation 2004; 77: 1215–1220 .

30.

Contreras G , Pardo V , Leclercq B et al. Sequential therapies for proliferative lupus nephritis . N Engl J Med 2004; 350: 971–980 .

31.

Ginzler EM , Dooley MA , Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis . N Engl J Med 2005; 353: 2219–2228 .